TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is a progressive condition that affects the arteries in the lungs, specifically the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Telaglenastat is not currently approved by the Food and Drug Administration for the treatment of PH. However, the study investigators believe that Telaglenastat may help lower blood pressure in the lungs and improve both heart and lung function. It is important to note that the drug will not be available to participants once the study concludes.

NCT Number	NCT07223528
Lead Sponsor	Chan, Stephen, MD, PhD Collaborators: Synhale Theraputics
Conditions	Pulmonary Hypertension
Enrollment	28 participants
Start Date	2026-08
Primary Completion	2028-09 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2026-04-07